The incidence and relative risk factors for developing cancer among patients with schizophrenia: A nine-year follow-up study

Chou, Frank Huang-Chih; Tsai, Kuan-Yi; Su, Chien-Ling; Lee, Ching‐Chih

doi:10.1016/j.schres.2011.02.018

Cited by 134 publications

(119 citation statements)

References 55 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…This finding was confirmed by Chou et al 29 who also tapped into the NHIRD in Taiwan. The increased cancer risks among female schizophrenia patients were also noted in other Asian populations.…”

Section: Discussionsupporting

confidence: 63%

“…First, we do not know whether schizophrenia with a longer duration (over 13 y) would confer a similarly lower cancer risk ratio. Using the NHIRD in Taiwan, Chou et al 29 selected schizophrenia patients obtaining the schizophrenia certificate from 1995 to 1999 and estimated their cancer incidence between 2000 and 2008. Their schizophrenia cohort mainly composed of those who were granted the certificate in 1995 and 1996.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer Incidence in Patients With Schizophrenia or Bipolar Disorder: A Nationwide Population-Based Study in Taiwan, 1997-2009

Lin

Chen

Kuo

et al. 2011

Schizophrenia Bulletin

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 63%

Section: Discussionmentioning

confidence: 99%

Cancer Incidence in Patients With Schizophrenia or Bipolar Disorder: A Nationwide Population-Based Study in Taiwan, 1997-2009

Lin

Chen

Kuo

et al. 2011

Schizophrenia Bulletin

View full text Add to dashboard Cite

“…We found 23% (adjusted) decreased performance of PSA tests among service users diagnosed with schizophrenia compared to their matched counterparts. In line with previous reports [1][2][3][4][5][6][7][8] we found that the risk of prostate cancer among service users with schizophrenia was lower than matched comparison subjects (in about 61%). According to our hypothesis, the lower rate of PSA tests could suggest that this negative association may reflect more an issue of method than an issue of substance.…”

Section: Discussionsupporting

confidence: 93%

“…Several studies found a reduced risk for cancer in persons diagnosed with schizophrenia [1][2][3][4][5][6][7] . Among cancer sites the most robust finding was associated with prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Lower risk of prostate cancer in schizophrenia: fact or artifact?

2014

View full text Add to dashboard Cite

-Background and Objectives: Reduced risk for prostate cancer in persons diagnosed with schizophrenia has been reported repeatedly. While genetic factors and antipsychotic medications were imputed, a methodological hypothesis could be raised: given the reported disparities of health services with regard to service users with schizophrenia these persons may be screened less often compared to schizophrenia-free counterparts resulting in undetected prostate tumors. The study objective was to compare the rates of performance of the prostate specific antigen (PSA) screening test among persons diagnosed with schizophrenia to matched-comparison subjects.Methods: A prospective historical epidemiological study which included service users with and without a diagnosis of schizophrenia (N = 52,131). Linkage was conducted between databases of the nation-wide psychiatric register and Israel's largest health maintenance organization. Annual performance of PSA tests was recorded between the years 2002-2009.Results: Service users with schizophrenia performed the PSA test 23% less than the comparison subjects. However, among service users who were diagnosed with prostate cancer only 44% performed the PSA test during the year prior to diagnosis.Conclusions: In line with our hypothesis, lower rates of PSA screening tests were conducted among service users with schizophrenia. However, the relatively low rate of this test prior to prostate cancer diagnosis ought to be noted.

show abstract

“…Due to the established safety of these drugs, combined with their proven ability to cross the BBB, antipsychotic medications are increasingly being tested for efficacy in patients with various cancers, including malignant brain tumors. Furthermore, epidemiological studies with diverse patient populations have reported significantly lower incidences of cancer among patients with schizophrenia compared with the general population (22)(23)(24)(25)(26)(27)(28)(29). These findings support the possibility that antipsychotics may partially ameliorate the risk of cancer development, although molecular elucidations are yet to be accomplished.…”

Section: Anti-neoplastic Effects Of Antipsychoticsmentioning

confidence: 82%

Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges

2016

View full text Add to dashboard Cite

Abstract. Glioblastoma multiforme (GBM) is the most common and most lethal primary brain tumor, with tragically little therapeutic progress over the last 30 years. Surgery provides a modest benefit, and GBM cells are resistant to radiation and chemotherapy. Despite significant development of the molecularly targeting strategies, the clinical outcome of GBM patients remains dismal. The challenges inherent in developing effective GBM treatments have become increasingly clear, and include resistance to standard treatments, the blood-brain barrier, resistance of GBM stem-like cells, and the genetic complexity and molecular adaptability of GBM. Recent studies have collectively suggested that certain antipsychotics harbor antitumor effects and have potential utilities as anti-GBM therapeutics. In the present review, the anti-tumorigenic effects and putative mechanisms of antipsychotics, and the challenges for the potential use of antipsychotic drugs as anti-GBM therapeutics are reviewed.

show abstract

The incidence and relative risk factors for developing cancer among patients with schizophrenia: A nine-year follow-up study

Cited by 134 publications

References 55 publications

Cancer Incidence in Patients With Schizophrenia or Bipolar Disorder: A Nationwide Population-Based Study in Taiwan, 1997-2009

Cancer Incidence in Patients With Schizophrenia or Bipolar Disorder: A Nationwide Population-Based Study in Taiwan, 1997-2009

Lower risk of prostate cancer in schizophrenia: fact or artifact?

Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges

Contact Info

Product

Resources

About